Axonics Updates On Inter Partes Review Proceedings; Plans To Seek Review Of The PTAB's Finding That Remaining Claims Were Not Unpatentable
Axonics Updates On Inter Partes Review Proceedings; Plans To Seek Review Of The PTAB's Finding That Remaining Claims Were Not Unpatentable
Today, the PTAB invalidated 10 of the 15 challenged claims in Medtronic's '314 patent and declined to invalidate the challenged claims in the '756 patent over one Administrative Patent Judge's dissenting opinion. The district court case where Medtronic has asserted these patents is currently stayed based on these IPRs as well as pending IPRs on other Medtronic asserted patents.
今天，PTAB宣佈美敦力314年專利中15項受質疑的索賠中的10項無效，並拒絕因一位行政專利法官的反對意見而宣佈756年專利中受到質疑的索賠無效。根據這些知識產權以及美敦力主張的其他專利的未決知識產權，美敦力主張這些專利的地方法院案件目前暫時擱置。
Raymond W. Cohen, chief executive officer, said, "Axonics will continue to vigorously defend itself against Medtronic's claims while we remain focused on fulfilling our mission of changing the lives of patients suffering from bladder and bowel dysfunction."
首席執行官雷蒙德·科恩表示：“Axonics將繼續大力捍衛自己免受美敦力的索賠，同時我們將繼續專注於履行改變膀胱和腸道功能障礙患者生活的使命。”
譯文內容由第三人軟體翻譯。